1-20 of 24
Keywords: Finasteride
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Subject Area:
Further Areas
European Urology (1992) 22 (4): 271–277.
Published Online: 11 August 2017
...H.O. Beisland; B. Binkowitz; E. Brekkan; P. Ekman; M. Kontturi; T. Lehtonen; P. Lundmo; F. Pappas; E. Round; D. Shapiro; E. Stoner; R. Swartz; E. Varenhorst The effects of finasteride, a potent 5a-reductase inhibitor, were assessed in patients with benign prostatic hyperplasia. Patients were...
Journal Articles
Subject Area:
Further Areas
European Urology (1996) 30 (2): 269–278.
Published Online: 11 August 2017
... Chemoprevention for Prostatic Intraepithelial Neoplasia Key Words Chemoprevention Prostate intraepithelial neoplasia Prostate carcinoma Finasteride Abstract Objectives: To evaluate the potential application of chemoprevention strate­ gies in prostatic intraepithelial neoplasia. Methods: Review of relevant litera­...
Journal Articles
Subject Area:
Further Areas
European Urology (1993) 24 (Suppl. 2): 106–112.
Published Online: 11 August 2017
... of the 5α-reductase inhibitor finasteride and the antiandrogen flutamide was as effective as a luteinizing hormone-releasing hormone analog and flutamide in inhibiting the growth of the prostate. In a pilot trial, 10 potent patients with clinical stage C and D1 prostate cancer were given the combination...
Journal Articles
Subject Area:
Further Areas
European Urology (1993) 24 (1): 20–26.
Published Online: 11 August 2017
...Roger S. Kirby; Justin Vale; Jenny Bryan; Kate Holmes; Judith Webb A group of 69 men with bladder outflow obstruction due to benign prostatic hyperplasia (BPH) were treated in a double-blind placebo-controlled study with finasteride (Proscar), a 5α-reductase inhibitor, 5 mg or 10 mg/day...
Journal Articles
Subject Area:
Further Areas
European Urology (1995) 28 (4): 304–309.
Published Online: 11 August 2017
...Evon Moore; Bruce Bracken; William Bremner; Jack Geller; Julianne Imperato-McGinley; John McConnel; Johnny Roy; Lisa Trevor; Darracotto Vaughan; Frances Pappas; Thomas Cook; Glenn Gormley; Elizabeth Stoner We assessed the long-term safety and efficacy of finasteride, an orally active 5α-reductase...
Journal Articles
Subject Area:
Further Areas
European Urology (1991) 20 (Suppl. 1): 78–81.
Published Online: 11 August 2017
... were administered varying doses of the 5α-reductase inhibitor finasteride. Finasteride was found to be a potent inhibitor of both C(19) androgen and C(21) 5α-steroid metabolism affecting both hepatic and peripheral 5α-metabolism. The 5α-steroid metabolite profile was strikingly similar to that of MPHs...
Journal Articles
Journal Articles
Subject Area:
Further Areas
European Urology (1999) 35 (5-6): 544–547.
Published Online: 16 April 2012
... approximately 5 years ago and will achieve its primary endpoint in October 2004. At the start of the study, 18,882 men, aged over 55 years, and with normal digital rectal examination (DRE) and serum prostate-specific antigen (PSA) levels of ≤3.0 ng/ml were randomized to take finasteride (5 mg/day) or placebo (1...
Journal Articles
Subject Area:
Further Areas
European Urology (2001) 40 (Suppl. 4): 1–4.
Published Online: 19 December 2001
... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. BHP LUTS Disease management Real life practice Quality of life α 1 -Adrenoceptor α 1 -Adrenoceptor antagonist Finasteride Surgery Lower urinary tract symptoms...
Journal Articles
Subject Area:
Further Areas
European Urology (2001) 40 (Suppl. 4): 21–30.
Published Online: 19 December 2001
... such as alfuzosin and tamsulosin may reduce the risk of treatment failure with a comparable rate to finasteride. Although the different α 1 -AR antagonists are equivalent in efficacy they differ in tolerability with the subtype selective tamsulosin having the lowest risk for interference with blood pressure...
Journal Articles
Subject Area:
Further Areas
European Urology (2001) 39 (Suppl. 3): 20–25.
Published Online: 15 March 2001
... to complications such as acute urinary retention or can ultimately require surgical treatment. In a placebo-controlled study finasteride was shown to reduce the incidence of acute urinary retention and the need for surgery in patients with LUTS suggestive of BPO. While α 1 -adrenoceptor antagonists are superior...
Journal Articles
Subject Area:
Further Areas
European Urology (2000) 38 (Suppl. 1): 48–53.
Published Online: 24 November 2000
... of LUTS/BPH and assess the effectiveness of medical therapy between 1992 and 1998. Methods: 61,364 men with LUTS/BPH and without a record of prostatic cancer were identified on the database. 14,195 were treated with an α 1 -blocker or finasteride. Treatment failure was defined as prostatic surgery...
Journal Articles
Subject Area:
Further Areas
European Urology (2000) 38 (Suppl. 1): 40–47.
Published Online: 24 November 2000
...(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. α 1 -Adrenoceptor antagonists Finasteride Phytotherapy Lower urinary tract symptoms Benign prostatic obstruction...
Journal Articles
Subject Area:
Further Areas
European Urology (2000) 38 (Suppl. 1): 18–24.
Published Online: 24 November 2000
... discussed. Methods: Information reviewed here comes mainly from published scientific articles and abstracts describing direct comparative trials among α 1 -adrenoceptor antagonists, finasteride, and/or phytotherapy. Results: Direct comparative trials demonstrated α 1 -adrenoceptor antagonists to be more...
Journal Articles
Journal Articles
Subject Area:
Further Areas
European Urology (2000) 37 (4): 367–380.
Published Online: 17 March 2000
... by reduction of testosterone. Two isoenzymes of 5α–reductase have been discovered. Type 1 is present in most tissues of the body where 5α–reductase is expressed and is the dominant form in sebaceous glands. Type2 5α–reductase is the dominant isoenzyme in genital tissues, including the prostate. Finasteride...
Journal Articles
Subject Area:
Further Areas
European Urology (1999) 36 (Suppl. 3): 40–51.
Published Online: 28 October 1999
... position is difficult to appraise because of the lack of appropriate long-term data from prospective, properly designed, controlled trials, also in terms of lack of data on cost-efficiency. Therefore, medical therapy with either finasteride or α 1 -blockers remains an attractive therapeutic alternative...
Journal Articles
Subject Area:
Further Areas
European Urology (1999) 36 (Suppl. 3): 28–32.
Published Online: 28 October 1999
... is more frequently used in Italy than in other European countries. Minimally invasive treatments remain a very small portion of interventions for the management of BPH in Italy. Fifty-five percent of patient days of treatment are α-blockers, 37% is finasteride. The share of α-blockers has dramatically...
Journal Articles
Subject Area:
Further Areas
European Urology (1999) 36 (Suppl. 3): 7–13.
Published Online: 28 October 1999
.... A survey among urologists determined that for men with mild symptoms, watchful waiting was employed 77% of the time, α 1 -adrenoceptor antagonists 21% and finasteride 1%. For those with moderate symptoms and prostate volume ≤40 ml, α 1 -adrenoceptor antagonists are employed 88% of the time, finasteride 1...
Journal Articles
Subject Area:
Further Areas
European Urology (1999) 36 (Suppl. 3): 33–39.
Published Online: 28 October 1999
... that for finasteride has remained flat. In 1998, α 1 -adrenoceptor antagonists had 64% market share and finasteride 36% from a total market of 53 million Euro. Conclusions: In the UK, challenges for the future management of symptomatic BPH will be the increased number of patients, further enhancement of efficient co...